scPharmaceuticals (FRA:2SX) Total Liabilities : €89.96 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is scPharmaceuticals Total Liabilities?

scPharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €89.96 Mil.

scPharmaceuticals's quarterly Total Liabilities increased from Jun. 2024 (€52.22 Mil) to Sep. 2024 (€85.02 Mil) and increased from Sep. 2024 (€85.02 Mil) to Dec. 2024 (€89.96 Mil).

scPharmaceuticals's annual Total Liabilities increased from Dec. 2022 (€48.86 Mil) to Dec. 2023 (€52.51 Mil) and increased from Dec. 2023 (€52.51 Mil) to Dec. 2024 (€89.96 Mil).

scPharmaceuticals Total Liabilities Historical Data

The historical data trend for scPharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Total Liabilities Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

22.09

19.97

48.86

52.51

89.96

scPharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															52.51	49.58	52.22	85.02	89.96

scPharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

scPharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.207	+	(50.094	+	-0.0010000000000154
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	25.66	+	0	+	0)
	=	89.96

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	102.681	-	12.721
	=	89.96

scPharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.207	+	(50.094	+	-0.0010000000000154
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	25.66	+	0	+	0)
	=	89.96

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	102.681	-	12.721
	=	89.96

scPharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SCPH:USA 2SX:Germany

Address

25 Mall Road, Suite 203, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals Headlines

No Headlines